Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The FDA formally kicked off its quinquennial process to reauthorize the federal user fee legislation that helps fund its ...

Skin-focused Sirona Biochem is liquidating its R&D subsidiary after a pair of financing deals and a licensing agreement with ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

A Senate committee has rejected President Donald Trump’s efforts to gouge funding for the National Institutes of Health (NIH) ...

Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical ...

OrbiMed’s website lists 134 biopharma companies across the firm’s portfolio. Recent investments the firm has participated in ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

The brain-computer interface developer Synchron has shown that its minimally invasive device can help connect a patient with ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Allogene Therapeutics has reported a patient death tied to its anti-CD52 monoclonal antibody used for lymphodepletion in its ...

A new Caribbean company has emerged to enter the increasingly crowded T-cell engager space. | A new Caribbean company has ...